Clinical trialsCompany release

Rejuvenate Biomed completes last patient visit in Phase 2 MINT-COPD trial of RJx-01

Rejuvenate Biomed NV · Mon 16 Nov 2026

The last participant has finished the final visit in the placebo-controlled study in older COPD patients, with topline data still expected by the end of 2026.

Rejuvenate Biomed announced on 16 November 2026 that the last patient has completed the final visit in MINT-COPD, its randomised, placebo-controlled Phase 2 trial of RJx-01.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Rejuvenate Biomed NV ↗

Article written by VigiEye from the official source (Rejuvenate Biomed NV). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →